Skip to Main Content

BioMarin’s experimental hemophilia gene therapy, which is expected to be approved by U.S. regulators in August, has continued to prevent bleeding in patients treated four years ago.

However, levels of the key clotting protein the treatment helps produce, Factor VIII, continued to slowly decline, potentially leading to questions as to how long-lasting the benefits might be.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED